These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 10968704)

  • 1. Immunohistologic evaluation of metastatic carcinomas of unknown origin: an algorithmic approach.
    DeYoung BR; Wick MR
    Semin Diagn Pathol; 2000 Aug; 17(3):184-93. PubMed ID: 10968704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunocytochemical identification of carcinomas of unknown primary in serous effusions.
    Pomjanski N; Grote HJ; Doganay P; Schmiemann V; Buckstegge B; Böcking A
    Diagn Cytopathol; 2005 Nov; 33(5):309-15. PubMed ID: 16240395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tissue microarrays are an effective quality assurance tool for diagnostic immunohistochemistry.
    Hsu FD; Nielsen TO; Alkushi A; Dupuis B; Huntsman D; Liu CL; van de Rijn M; Gilks CB
    Mod Pathol; 2002 Dec; 15(12):1374-80. PubMed ID: 12481020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm.
    Dennis JL; Hvidsten TR; Wit EC; Komorowski J; Bell AK; Downie I; Mooney J; Verbeke C; Bellamy C; Keith WN; Oien KA
    Clin Cancer Res; 2005 May; 11(10):3766-72. PubMed ID: 15897574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate.
    Sheridan T; Herawi M; Epstein JI; Illei PB
    Am J Surg Pathol; 2007 Sep; 31(9):1351-5. PubMed ID: 17721190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Skin metastases from unknown origin: role of immunohistochemistry in the evaluation of cutaneous metastases of carcinoma of unknown origin.
    Azoulay S; Adem C; Pelletier FL; Barete S; Francès C; Capron F
    J Cutan Pathol; 2005 Sep; 32(8):561-6. PubMed ID: 16115055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glyco- and immunohistochemical refinement of the differential diagnosis between mesothelioma and metastatic carcinoma and survival analysis of patients.
    Kayser K; Böhm G; Blum S; Beyer M; Zink S; André S; Gabius HJ
    J Pathol; 2001 Feb; 193(2):175-80. PubMed ID: 11180163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemical panel of undifferentiated orbital metastatic carcinomas.
    Godeiro KD; Odashiro AN; Odashiro DN; Fernandes BF; Burnier MN; Callejo S
    Orbit; 2007 Jun; 26(2):101-6. PubMed ID: 17613856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative study of monoclonal antibody B72.3 and gross cystic disease fluid protein-15 as markers of apocrine carcinoma of the breast.
    Honma N; Takubo K; Arai T; Younes M; Kasumi F; Akiyama F; Sakamoto G
    APMIS; 2006 Oct; 114(10):712-9. PubMed ID: 17004974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of cytokeratins and additional markers in undifferentiated lymph node metastases of the neck.
    Bartel-Friedrich S; Friedrich RE; Holzhausen HJ
    Anticancer Res; 2000; 20(6D):4931-40. PubMed ID: 11326642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent immunohistochemical markers in the differential diagnosis of primary and metastatic carcinomas of the liver.
    Gokden M; Shinde A
    Diagn Cytopathol; 2005 Sep; 33(3):166-72. PubMed ID: 16078249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Value of immunohistochemistry in confirming undifferentiated ovarian carcinomas.
    Georgescu CV; Florescu M; Simionescu C
    Rom J Morphol Embryol; 1999-2004; 45():133-42. PubMed ID: 15847387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Practical Applications in Immunohistochemistry: Carcinomas of Unknown Primary Site.
    Kandalaft PL; Gown AM
    Arch Pathol Lab Med; 2016 Jun; 140(6):508-23. PubMed ID: 26457625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monoclonal antibody MOC-31 reactivity as a marker for adenocarcinoma in cytologic preparations.
    Hecht JL; Pinkus JL; Pinkus GS
    Cancer; 2006 Feb; 108(1):56-9. PubMed ID: 16329115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metastatic carcinoma of unknown primary: diagnostic approach using immunohistochemistry.
    Conner JR; Hornick JL
    Adv Anat Pathol; 2015 May; 22(3):149-67. PubMed ID: 25844674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Germ cell tumors of the gonads: a selective review emphasizing problems in differential diagnosis, newly appreciated, and controversial issues.
    Ulbright TM
    Mod Pathol; 2005 Feb; 18 Suppl 2():S61-79. PubMed ID: 15761467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative immunohistochemical profile of hepatocellular carcinoma, cholangiocarcinoma, and metastatic adenocarcinoma.
    Lau SK; Prakash S; Geller SA; Alsabeh R
    Hum Pathol; 2002 Dec; 33(12):1175-81. PubMed ID: 12514785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anaplastic large-cell lymphoma with aberrant expression of multiple cytokeratins masquerading as metastatic carcinoma of unknown primary.
    Nguyen TT; Kreisel FH; Frater JL; Bartlett NL
    J Clin Oncol; 2013 Nov; 31(33):e443-5. PubMed ID: 23775969
    [No Abstract]   [Full Text] [Related]  

  • 19. Value of p63 and cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas.
    Kaufmann O; Fietze E; Mengs J; Dietel M
    Am J Clin Pathol; 2001 Dec; 116(6):823-30. PubMed ID: 11764070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical approaches to the diagnosis of undifferentiated malignant tumors.
    Wick MR
    Ann Diagn Pathol; 2008 Feb; 12(1):72-84. PubMed ID: 18164421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.